Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?

Core Viewpoint - Zimmer Biomet's shares have underperformed the S&P 500, losing about 0.5% in the past month, raising questions about its upcoming earnings release and potential for a breakout [1]. Group 1: Earnings Estimates and Trends - Fresh estimates for Zimmer Biomet have trended downward over the past month, indicating a negative outlook [2][4]. - The stock has a Zacks Rank of 4 (Sell), suggesting expectations of below-average returns in the coming months [4]. Group 2: VGM Scores - Zimmer Biomet has an average Growth Score of C, a Momentum Score of F, and a Value Score of B, placing it in the top 40% for value investment strategy [3]. - The aggregate VGM Score for Zimmer is C, which is relevant for investors not focused on a single strategy [3]. Group 3: Industry Performance Comparison - In comparison, Stryker, a competitor in the same medical products industry, has gained 0.9% over the past month and reported revenues of $5.87 billion, reflecting a year-over-year increase of 11.9% [5]. - Stryker's earnings per share (EPS) for the last quarter was $2.84, up from $2.50 a year ago, and it is expected to post an EPS of $3.06 for the current quarter, representing a year-over-year change of 8.9% [5][6].